Skip to main content
SpringerLink
Log in

Selective Internal Radiotherapy (SIRT) of Primary Hepatic Carcinoma and Liver Metastases

  • Chapter
  • First Online:
Nuclear Medicine Therapy

  • 850 Accesses

Abstract

SIRT (selective internal radiation therapy) is a widely used form of intra-arterial treatment for patients with advanced liver primary and secondary tumors of the liver. The relatively selective arterial perfusion via the hepatic artery of growing liver tumors makes intra-arterial treatment an near ideal concept for these patients. Nevertheless the procedure needs technical and dosimetry skills which are summarized in this chapter. Furthermore, the clinical data in context to intravenous therapies need to be acknowledged mainly in discussion with multidisciplinary tumor boards. Therefore this chapter also summarizes important studies in the field. Finally, measurement outcome remains a challenge and are also discussed in the last paragraph.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gulec SA, Mesoloras G, Stabin M. Dosimetric techniques in 90Y-microsphere therapy of liver cancer: the MIRD equations for dose calculations. J Nucl Med. 2006;47:1209–11.

    CAS  PubMed  Google Scholar 

  2. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Kulik L, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64. https://doi.org/10.1053/j.gastro.2009.09.006.

    Article  CAS  PubMed  Google Scholar 

  3. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–78. https://doi.org/10.1002/hep.24451.

    Article  Google Scholar 

  4. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux G-P, Marthey L, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36. https://doi.org/10.1016/s1470-2045(17)30683-6.

    Article  CAS  PubMed  Google Scholar 

  5. Chow PKH, Gandhi M, Tan S-B, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–21. https://doi.org/10.1200/jco.2017.76.0892.

    Article  CAS  PubMed  Google Scholar 

  6. Chauhan N, Bukovcan J, Boucher E, Cosgrove D, Edeline J, Hamilton B, Salem R, et al. Intra-arterial therasphere yttrium-90 glass microspheres in the treatment of patients with unresectable hepatocellular carcinoma: protocol for the STOP-HCC phase 3 randomized controlled trial. JMIR Res Protoc. 2018;7(8):e11234. https://doi.org/10.2196/11234.

    Article  PubMed  Google Scholar 

  7. Levi Sandri GB, Ettorre GM, Giannelli V, Colasanti M, Sciuto R, Pizzi G, Lucatelli P, et al. Trans-arterial radio-embolization: a new chance for patients with hepatocellular cancer to access liver transplantation, a world review. Transl Gastroenterol Hepatol. 2017;2(11):98. https://doi.org/10.21037/tgh.2017.11.11.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Vouche M, Lewandowski RJ, Atassi R, Memon K, Gates VL, Ryu RK, Salem R, et al. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection. J Hepatol. 2013;59(5):1029–36. https://doi.org/10.1016/j.jhep.2013.06.015.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Salem R, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9(8):1920–8. https://doi.org/10.1111/j.1600-6143.2009.02695.x.

    Article  CAS  PubMed  Google Scholar 

  10. Gabr A, Abouchaleh N, Ali R, Baker T, Caicedo J, Katariya N, Salem R, et al. Outcomes of surgical resection after radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2018;29(11):1502–1510.e1. https://doi.org/10.1016/j.jvir.2018.06.027.

    Article  PubMed  Google Scholar 

  11. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, Flamen P, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28(23):3687–94. https://doi.org/10.1200/jco.2010.28.5643.

    Article  CAS  PubMed  Google Scholar 

  12. Sharma RA, Van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D, Steward WP, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol. 2007;25(9):1099–106. https://doi.org/10.1200/jco.2006.08.7916.

    Article  CAS  PubMed  Google Scholar 

  13. van Hazel GA, Heinemann V, Sharma NK, Findlay MPN, Ricke J, Peeters M, Gibbs P, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol. 2016;34(15):1723–31. https://doi.org/10.1200/jco.2015.66.1181.

    Article  PubMed  Google Scholar 

  14. Dutton SJ, Kenealy N, Love SB, Wasan HS, Sharma RA. FOXFIRE protocol: an open-label, randomised, phase III trial of 5-fluorouracil, oxaliplatin and folinic acid (OxMdG) with or without interventional Selective Internal Radiation Therapy (SIRT) as first-line treatment for patients with unresectable liver-only or liver-dominant metastatic colorectal cancer. BMC Cancer. 2014;14(1):497. https://doi.org/10.1186/1471-2407-14-497.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, Westcott M, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. Lancet Oncol. 2017;18(9):1159–71. https://doi.org/10.1016/s1470-2045(17)30457-6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Clinicaltrial.gov trial number : NCT01483027.

    Google Scholar 

  17. Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, Salem R, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31(3):271–9. https://doi.org/10.1097/coc.0b013e31815e4557.

    Article  PubMed  Google Scholar 

  18. Peker A, Çiçek O, Soydal Ç, Küçük NÖ, Bilgiç S. Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Diagn Interv Radiol. 2015;21(1):54–9.

    Article  Google Scholar 

  19. Bangash AK, Atassi B, Kaklamani V, Rhee TK, Yu M, Lewandowski RJ, Sato KT, Ryu RK, Gates VL, Newman S, Mandal R, Gradishar W, Omary RA, Salem R. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol. 2007;18(5):621–8.

    Article  Google Scholar 

  20. Fendler WP, Lechner H, Todica A, Paprottka KJ, Paprottka PM, Jakobs TF, Haug AR, et al. Safety, efficacy, and prognostic factors after radioembolization of hepatic metastases from breast cancer: a large single-center experience in 81 patients. J Nucl Med. 2016;57(4):517–23. https://doi.org/10.2967/jnumed.115.165050.

    Article  CAS  PubMed  Google Scholar 

  21. Eldredge-Hindy H, Ohri N, Anne PR, Eschelman D, Gonsalves C, Intenzo C, Sato T, et al. Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma. Am J Clin Oncol. 2016;39(2):189–95. https://doi.org/10.1097/coc.0000000000000033.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Tulokas S, Mäenpää H, Peltola E, Kivelä T, Vihinen P, Virta A, Hernberg M, et al. Selective internal radiation therapy (SIRT) as treatment for hepatic metastases of uveal melanoma: a Finnish nation-wide retrospective experience. Acta Oncol. 2018;57(10):1373–80. https://doi.org/10.1080/0284186x.2018.1465587.

    Article  PubMed  Google Scholar 

  23. Mouli S, Memon K, Baker T, Benson AB III, Mulcahy MF, Gupta R, Lewandowski RJ, et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol. 2013;24(8):1227–34. https://doi.org/10.1016/j.jvir.2013.02.031.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Gangi A, Shah J, Hatfield N, Smith J, Sweeney J, Choi J, Kis B, et al. Intrahepatic cholangiocarcinoma treated with transarterial yttrium-90 glass microsphere radioembolization: results of a single institution retrospective study. J Vasc Interv Radiol. 2018;29(8):1101–8. https://doi.org/10.1016/j.jvir.2018.04.001.

    Article  PubMed  Google Scholar 

  25. Lewandowski RJ, Thurston KG, Goin JE, et al. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging. J Vasc Interv Radiol. 2005;16(12):1641–51.

    Article  Google Scholar 

  26. Szyszko T, Al-Nahhas A, Canelo R, et al. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography. Nucl Med Commun. 2007;28(1):15–20.

    Article  Google Scholar 

  27. Sabet A, Meyer C, Aouf A, et al. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. Eur J Nucl Med Mol Imaging. 2015;42(3):370–6.

    Article  CAS  Google Scholar 

  28. Sabet A, Ahmadzadehfar H, Bruhman J, et al. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET. Nuklearmedizin. 2014;53(2):39–45. https://doi.org/10.3413/Nukmed-0622-13-09.

    Article  CAS  PubMed  Google Scholar 

  29. Haug AR, Tiega Donfack BP, Trumm C, et al. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med. 2012;53(3):371–7.

    Article  CAS  Google Scholar 

  30. Haug AR, Heinemann V, Bruns CJ, et al. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2011;38:1037–45.

    Article  CAS  Google Scholar 

  31. Michl M, Lehner S, Paprottka PM, et al. Use of PERCIST for prediction of progression-free and overall survival after radioembolization for liver metastases from pancreatic cancer. J Nucl Med. 2016;57(3):355–60.

    Article  CAS  Google Scholar 

  32. Barabasch A, Kraemer NA, Ciritsis A, et al. Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization. Investig Radiol. 2015;50(6):409–15.

    Article  Google Scholar 

  33. Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118(1):147–56.

    Article  CAS  Google Scholar 

  34. Shady W, Sotirchos VS, Do RK, et al. Surrogate imaging biomarkers of response of colorectal liver metastases after salvage radioembolization using 90Y-loaded resin microspheres. AJR Am J Roentgenol. 2016;207(3):661–70.

    Article  Google Scholar 

  35. van den Hoven AF, Rosenbaum CE, Elias SG, et al. Insights into the dose-response relationship of radioembolization with resin 90Y-microspheres: a prospective cohort study in patients with colorectal cancer liver metastases. J Nucl Med. 2016;57(7):1014–9.

    Article  Google Scholar 

  36. Arranja AG, Hennink WE, Denkova AG, Hendrikx RWA, Nijsen JFW. Radioactive holmium phosphate microspheres for cancer treatment. Int J Pharm. 2018;548(1):73–81. https://doi.org/10.1016/j.ijpharm.2018.06.036.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, University Hospital of Lausanne, Lausanne, Switzerland

    Niklaus Schaefer

Authors
  1. Niklaus Schaefer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Niklaus Schaefer .

Editor information

Editors and Affiliations

  1. Nuclear Medicine and PET/CT Centre, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

    Luca Giovanella

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Schaefer, N. (2019). Selective Internal Radiotherapy (SIRT) of Primary Hepatic Carcinoma and Liver Metastases. In: Giovanella, L. (eds) Nuclear Medicine Therapy. Springer, Cham. https://doi.org/10.1007/978-3-030-17494-1_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-17494-1_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-17493-4

  • Online ISBN: 978-3-030-17494-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation